Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL

Zanubrutinib is a potent and highly selective inhibitor of Bruton tyrosine kinase (BTK). In this first-in-human, open-label, multicenter, phase 1 study, patients in part 1 (3 + 3 dose escalation) had relapsed/refractory B-cell malignancies and received zanubrutinib 40, 80, 160, or 320 mg once daily...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Blood
Hoofdauteurs: Tam, Constantine S., Trotman, Judith, Opat, Stephen, Burger, Jan A., Cull, Gavin, Gottlieb, David, Harrup, Rosemary, Johnston, Patrick B., Marlton, Paula, Munoz, Javier, Seymour, John F., Simpson, David, Tedeschi, Alessandra, Elstrom, Rebecca, Yu, Yiling, Tang, Zhiyu, Han, Lynn, Huang, Jane, Novotny, William, Wang, Lai, Roberts, Andrew W.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Hematology 2019
Onderwerpen:
Clinical Trials and Observations
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6742923/
https://ncbi.nlm.nih.gov/pubmed/31340982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2019001160
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items